论文部分内容阅读
目的探究在前列腺增生的临床治疗中应用经尿道汽化电切术的治疗效果以及安全性。方法 92例前列腺增生患者,结合患者接受诊治的先后顺序进行分组,将单号设定为对照组,双号设定为观察组,各46例。对照组患者应用经尿道电切术进行治疗,观察组患者则应用经尿道汽化电切术进行治疗,对比两组患者手术后的病情恢复效果以及治疗期间的不良反应发生情况。结果观察组患者手术后增生残余量为(11.30±6.20)ml、前列腺症状评分为(7.50±3.19)分以及生活质量评分为(1.60±0.20)分,对照组增生残余量为(75.20±15.20)ml,前列腺症状评分为(28.50±7.19)分,生活质量评分为(5.60±1.02)分;观察组增生残余量、前列腺症状评分及生活质量评分均优于对照组,差异有统计学意义(P<0.05)。结论在前列腺增生的临床治疗中结合经尿道汽化电切术进行治疗能够有效改善患者的治疗效果,值得在临床治疗中推广应用。
Objective To investigate the therapeutic effect and safety of transurethral electrovaporization in the clinical treatment of benign prostatic hyperplasia. Methods A total of 92 patients with BPH were divided into the following groups according to the order of their diagnosis and treatment: the single number was set as the control group and the double number was set as the observation group with 46 cases each. The patients in the control group were treated with transurethral resection of the transurethral resection. The patients in the observation group were treated with transurethral vaporization and resection of the transurethral resection of the transurethral resection. The recovery of the disease and the adverse reactions during the treatment were compared between the two groups. Results The postoperative residual volume of the patients in the observation group was (11.30 ± 6.20) ml, the score of prostate symptoms was (7.50 ± 3.19) and the quality of life score was (1.60 ± 0.20), while the residual volume of the control group was (75.20 ± 15.20) (P> 0.05). Prostate symptom score was (28.50 ± 7.19) and quality of life score was (5.60 ± 1.02). Proliferation residuals, prostate symptom scores and quality of life scores of the observation group were better than those of the control group (P <0.05). Conclusion In the clinical treatment of benign prostatic hyperplasia combined with transurethral electrovaporization of the treatment can effectively improve the therapeutic effect of patients, it is worth in the clinical treatment of the promotion and application.